ReviewBlood2013
Applications of high-throughput DNA sequencing to benign hematology.
Review in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users' views.BMC medical genomics · 2016Pooled it
- The Molecular Pathology of Non-Malignant Haematological Disease.British journal of biomedical science · 2026Review
- LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study.Clinical and translational medicine · 2025Article
- Integrative analysis reveals that SLC38A1 promotes hepatocellular carcinoma development via PI3K/AKT/mTOR signaling via glutamine mediated energy metabolism.Journal of cancer research and clinical oncology · 2023Article
- Anemia in the pediatric patient.Blood · 2022Article
- Whole-exome sequencing identifies an α-globin cluster triplication resulting in increased clinical severity of β-thalassemia.Cold Spring Harbor molecular case studies · 2017Article
- Diagnostic approaches for inherited hemolytic anemia in the genetic era.Blood research · 2017Review
- Whole-Exome Sequencing Identifies Loci Associated with Blood Cell Traits and Reveals a Role for Alternative GFI1B Splice Variants in Human Hematopoiesis.American journal of human genetics · 2016Article
- Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia.Cold Spring Harbor molecular case studies · 2016Article
- Insight into GATA1 transcriptional activity through interrogation of cis elements disrupted in human erythroid disorders.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Society for Pediatric Research 2015 Young Investigator Award: genetics of human hematopoiesis-what patients can teach us about blood cell production.Pediatric research · 2016Review
- Human and murine erythropoiesis.Current opinion in hematology · 2015Review
- X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation.The Journal of clinical investigation · 2015Article
- Article
- Altered chromatin occupancy of master regulators underlies evolutionary divergence in the transcriptional landscape of erythroid differentiation.PLoS genetics · 2014Article
- Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The development of novel technologies for high-throughput DNA sequencing is having a major impact on our ability to measure and define normal and pathologic variation in humans. This review discusses advances in DNA sequencing that have been applied to benign hematologic disorders, including those affecting the red blood cell, the neutrophil, and other white blood cell lineages. Relevant examples of how these approaches have been used for disease diagnosis, gene discovery, and studying complex traits are provided. High-throughput DNA sequencing technology holds significant promise for impacting clinical care. This includes development of improved disease detection and diagnosis, better understanding of disease progression and stratification of risk of disease-specific complications, and development of improved therapeutic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of therapy by genomic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.